AclarionACON
About: Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
Employees: 6
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
29% more funds holding
Funds holding: 7 [Q1] → 9 (+2) [Q2]
5% more capital invested
Capital invested by funds: $89.4K [Q1] → $94.2K (+$4.72K) [Q2]
0.2% more ownership
Funds ownership: 3.81% [Q1] → 4.01% (+0.2%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Ascendiant Capital Lucas Ward 10% 1-year accuracy 1 / 10 met price target | 720%upside $1.50 | Buy Maintained | 26 Aug 2024 |
Ascendiant Capital Lucas Ward 10% 1-year accuracy 1 / 10 met price target | 774%upside $1.60 | Buy Initiated | 29 Jul 2024 |
Financial journalist opinion
Based on 4 articles about ACON published over the past 30 days